Loading...
IMMX logo

Immix Biopharma, Inc.NasdaqCM:IMMX Stock Report

Market Cap US$868.5m
Share Price
n/a
1Y484.2%
7D-12.2%
1D0.6%
Portfolio Value
​
View

Immix Biopharma, Inc.

NasdaqCM:IMMX Stock Report

Market Cap: US$868.5m

Immix Biopharma (IMMX) Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. More details

IMMX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 82.1% below our estimate of its fair value

Revenue is forecast to grow 64.4% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years


IMMX Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW443,759 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
443,759 investors already sharing narratives
View all narratives

Immix Biopharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Immix Biopharma
Historical stock prices
Current Share PriceUS$12.21
52 Week HighUS$15.10
52 Week LowUS$1.94
Beta0.20
1 Month Change11.30%
3 Month Change39.70%
1 Year Change484.21%
3 Year Change360.75%
5 Year Changen/a
Change since IPO232.70%

Recent News & Updates

Recent updates

Analysis Article • Aug 13

We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 08

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 11

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Aug 12

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 28

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Immix Biopharma ( NASDAQ:IMMX...
Analysis Article • Jul 12

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 29

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 13

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 21

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

IMMXUS BiotechsUS Market
7D-12.2%-3.9%-1.5%
1Y484.2%40.0%13.3%

Return vs Industry: IMMX exceeded the US Biotechs industry which returned 38% over the past year.

Return vs Market: IMMX exceeded the US Market which returned 13.9% over the past year.

Price Volatility

Is IMMX's price volatile compared to industry and market?
IMMX volatility
IMMX Average Weekly Movement11.6%
Biotechs Industry Average Movement9.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: IMMX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: IMMX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201221Ilya Rachmanwww.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc. Fundamentals Summary

How do Immix Biopharma's earnings and revenue compare to its market cap?
IMMX fundamental statistics
Market capUS$868.49m
Earnings (TTM)-US$39.92m
Revenue (TTM)n/a
0.0x
P/S Ratio
-21.9x
P/E Ratio

Is IMMX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$39.92m
Earnings-US$39.92m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.56
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMMX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 06:35
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immix Biopharma, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Reni BenjaminCitizens JMP Securities, LLC
Jyoti PrakashEdison Investment Research